Sp901
THE NEXT THERAPEUTIC FRONTIER IN IBD — WHERE ARE WE WITH TARGETING FIBROSIS?
Date
May 8, 2023
Explore related products in the following collection:
Tracks
Related Products
CHANGES IN THERAPY ARE NOT ASSOCIATED WITH INCREASED REMISSION IN PATIENTS WITH CROHN’S DISEASE OF THE POUCH
BACKGROUND: Prevention of postoperative recurrence (POR) in Crohn’s disease (CD) after ileo-colonic (IC) resection is still a highly debated topic. Prophylactic immunosuppression after surgery is currently recommended in presence of at least one clinical risk factor (RF)…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
PANEL DISCUSSION
Technology is pervasive and its role in healthcare continues to grow. This session will give attendees hand on tips to consider how three key technological innovations are transforming GI care: artificial intelligence, social media, electronic medical records and new endoscopic technology…
DO ANXIETY AND DEPRESSION GO UNRECOGNIZED IN SOCIALLY VULNERABLE PATIENTS WITH INFLAMMATORY BOWEL DISEASE?
Background: Patients with inflammatory bowel disease (IBD) often modify their diet in attempt to manage their disease and symptoms. In some cases, dietary changes involve excessive restriction, which may place patients at risk for adverse consequences…